激活素A在多发性骨髓瘤发病中的研究进展

Research Progress of Activin A in Pathogenesis of Multiple Myeloma

多发性骨髓瘤（MM）是恶性浆细胞肿瘤,引起血钙升高、肾损害贫血和骨损害（CRAB症状,症状性骨髓瘤）。在MM患者中,高水平的激活素A不仅与MM的病情进展有关,与MM的溶骨性骨质破坏、贫血也相关,且影响MM患者的预后。抗激活素A疗法的应用,不仅可治疗MM相关的骨质破坏、贫血,也能改善MM患者的预后,故激活素A可能是MM或肿瘤性骨病的有希望的治疗靶点,特别是合并肿瘤性贫血的患者。

Multiple myeloma（MM） is a malignant plasma cell tumor that causes elevated blood calcium,anemia,kidney damage,and bone destruction（CRAB symptoms,symptomatic myeloma）. In MM patients,high levels of activin A are not only related to the progression of MM,but also related to osteolytic bone destruction and anemia,affecting the prognosis of MM patients. The application of anti-activin A therapy can treat MM-related bone destruction and anemia,and improve the survival of MM patients,so activin A may be a promising therapeutic target for MM or tumor-induced bone disease,especially for patients with tumor-related anemia.